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Abstract: The purpose of this study was to assess cost variability in the care of abdominal painassociated functional gastrointestinal disorders (AP-FGIDS) in youth across health systems, races,
and specific AP-FGID diagnoses. Patients, aged 8–17 years, with a priority 1 diagnosis corresponding
to a Rome IV defined AP-FGID were identified within the Health Facts® database. Total costs
were obtained across the continuum of care including outpatient clinics, emergency department,
and inpatient or observation units. Cost variability was described comparing different health
systems, races, and diagnoses. Thirteen thousand two hundred and fourteen patients were identified
accounting for 17,287 encounters. Total costs were available for 38.7% of the encounters. There was
considerable variability in costs within and, especially, across health systems. Costs also varied across
race, urban vs. rural site of care, and AP-FGID diagnoses. In conclusion, there was considerable
variability in the costs for care of AP-FGIDs which is sufficient to support multi-site studies to
understand the value of specific tests and treatments. Significant differences in costs by race merit
further investigation to understand key drivers.
Keywords: functional gastrointestinal disorders; irritable bowel syndrome; functional dyspepsia;
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Pediatric chronic abdominal pain is a common problem with a worldwide prevalence
rate of 13.5% [1]. Most will fulfill criteria for an abdominal pain-associated functional
gastrointestinal disorder (AP-FGID). There are four AP-FGIDS in youth: irritable bowel
syndrome (IBS), functional dyspepsia, abdominal migraine, and functional abdominal pain
syndrome [2].
The costs of care of pediatric AP-FGIDs are significant and continue to rise [3–5]. These
costs are particularly high in patients who are unresponsive or only partially responsive
to treatment [6]. In addition, up to 30% of AP-FGIDs persist into adulthood, where
the health care costs of IBS alone are over USD 20 billion per year [3,4]. Unfortunately,
there are currently no evidence-based pediatric practice guidelines to direct care of these
patients. There is a critical need to assess treatment in terms of value or, in other words,
the outcomes relative to costs [6,7]. This could be accomplished through multi-site quality
improvement projects provided there is sufficient variability in outcomes and/or costs
among centers. Currently, there is no process available to assess outcomes across healthcare
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systems; however, databases are available to assess costs across healthcare systems and
AP-FGID diagnoses.
Most previous studies regarding costs have been performed within single sites or
utilizing large databases with only emergency department (ED) and/or inpatient data
without outpatient clinic cost data. A recent study utilizing a nationally managed healthcare plan database reported total yearly costs (whether directly related to IBS or not) in
1215 pediatric IBS patients across outpatient and inpatient encounters [8]. Data included
costs related to IBS as well as costs unrelated to IBS. The Cerner Health Facts® database
(Cerner Corporation, North Kansas City, MO, USA) is one of the largest single vendor
electronic health record (EHR) databases. It provides multi-site longitudinal data regarding
outpatient/clinic, ED, and inpatient/observation encounters, making it an ideal source to
assess total costs across the continuum of care for youth with AP-FGIDs.
The primary objectives of the current study were to assess variability in direct costs
accrued in the care of AP-FGIDs in youth across healthcare systems, races, ages, gender,
and AP-FGID diagnoses.
2. Materials and Methods
This study was conducted utilizing a single vendor database, Cerner Health Facts®
(Cerner Corporation, North Kansas City, MO, USA). Cerner Corporation is a leading
EHR vendor and maintains a publicly available database including data from facilities
geographically distributed across the United States. The database contains data from
over 68 million patients from 664 facilities within 100 non-affiliated healthcare systems.
Health Facts contains data extracted from electronic health records (EHRs) under a data
use agreement between Cerner Corporation and individual systems utilizing the Cerner
EHR. The database contains data across the continuum of care including outpatient, clinic,
emergency department, observation, and inpatient encounters. The data are collected in a
longitudinal fashion. Consent and assent were waived by the Institutional Review Board
of Children’s Mercy.
2.1. Patients
We included all patients meeting an ICD-9 or ICD-10 code corresponding to an APFGID, who were between 8 and 17 years of age and who received care from 2010 to 2017.
Only encounters with priority 1 AP-FGID diagnoses were utilized. A priority 1 designation
indicates that the AP-FGID was the primary reason for the encounter as designated by the
care provider. Diagnoses, diagnostic codes, and the % of the total sample for each diagnosis
are shown in Table 1.
Table 1. Diagnostic codes utilized to identify various abdominal pain-associated functional gastrointestinal disorders.
Diagnosis

ICD-9 Codes

% of Total

Abdominal Migraine

346.8; 789.06

3.2%

Functional Dyspepsia
Irritable Bowel
Syndrome

536.8

37.1%

564.1

28.2%

ICD-10 Codes
G43.D0;
G43.D1
K30;
K58.0; K58.1
K58.2; K58.8; K58.9

% of Total
2.3%
13.8%
15.4%

2.2. Variables
In addition to demographic data (i.e., age, gender, and race), we assessed the geographic region and urban/rural status to ensure broad representation in the sample. The
study variables included the total charges per encounter across: (1) healthcare systems,
(2) races, (3) age groups, (4) urban/rural site of care, and (5) diagnoses. Within Health
Facts, the race category also includes the ethnic group “Hispanic”.
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Total costs were reported by 46 of the 77 health systems with total charge information
Total costs were reported by 46 of the 77 health systems with total charge information
available for 38.7% of the encounters overall. There was considerable variation in total
available for 38.7% of the encounters overall. There was considerable variation in total
costs within and across systems. The distribution of total encounter costs across health
costs within and across systems. The distribution of total encounter costs across health
systems are shown on a logarithmic scale in Figure 2.
systems are shown on a logarithmic scale in Figure 2.
The median costs and cost distributions by race/ethnicity for children (8–12 years of
age) and adolescents (13–17 years of age) are shown in Figure 3. While age appeared to
have only a small influence, there was variability by race/ethnicity with generally higher
costs for Hispanics and lower costs for Native Americans. The relatively high number of
consecutive outliers for these two groups suggests that costs may have had a bi-modal or
multi-modal distribution which could be obscured in the box plots.
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The median costs and cost distributions by race/ethnicity for children (8–12 years of
age) and adolescents (13–17 years of age) are shown in Figure 3. While age appeared to
have only a small influence, there was variability by race/ethnicity with generally higher
costs for Hispanics and lower costs for Native Americans. The relatively high number of
consecutive outliers for these two groups suggests that costs may have had a bi-modal or
multi-modal distribution which could be obscured in the box plots.
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4. Discussion
The economics of abdominal pain-associated FGIDs need to be considered in the context of overall health care economics. Globally, healthcare expenditures continue to rise,
outpacing gross domestic product (GDP) growth in Europe, North America, and the
world’s emerging economies such as the BRICS nations (Brazil, Russia, India, China, and
South Africa) [9,10]. Growth in total health expenditures is multi-factorial, driven in part
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4. Discussion
The economics of abdominal pain-associated FGIDs need to be considered in the
context of overall health care economics. Globally, healthcare expenditures continue to
rise, outpacing gross domestic product (GDP) growth in Europe, North America, and
the world’s emerging economies such as the BRICS nations (Brazil, Russia, India, China,
and South Africa) [9,10]. Growth in total health expenditures is multi-factorial, driven in
part by longer life expectancy and aging populations as well as advances in technology
and therapeutics, in addition to public demand [9]. However, it is mostly driven by
common health conditions including non-infectious diseases [10]. Increases in healthcare
spending and improvement in disease burden have not been equal across socioeconomic
groups [11,12].
The economic impact of IBS has been well studied within Europe and North America
with some data from Asia and the Middle East, demonstrating high direct and indirect
costs including loss of productivity [13–15]. In a study of six European countries, in
spite of the differences in healthcare systems, direct costs were similar and driven largely
by emergency department visits and hospitalizations [7]. Expenditures were similar to
those in the United States, although another review demonstrated higher costs in the
United States [14]. A study in China found strikingly similar results, with the major drivers
of costs being inpatient and outpatient care and loss of productivity accounting for 25% of
all costs [15]. IBS accounted for 3.3% of the total healthcare budget in China [15]. While
numerous studies have assessed the costs of IBS in adults, there are much less data for
children, which prompted the current study.
In the current study, there was considerable variability between health systems (and
to a lesser degree within single systems) with regards to direct costs in the care of APFGIDs in youth. Perhaps this is not unexpected, as there are no evidence-based guidelines
to direct evaluation and treatment. Variability could be explained, to some degree, by
differences in regional algorithms for diagnosis and treatment. Previous studies have
reported high variability in costs even within single systems. Dhroove and colleagues
evaluated the cost of the diagnostic evaluation in children with chronic abdominal pain
and demonstrated a cost range from just over USD 1000 to nearly USD 21,000 within
a single institution [4]. Costs were significantly affected by whether an endoscopy was
performed. Lane and colleagues evaluated costs within a single pediatric healthcare
network and found that referral to a gastroenterologist increased costs five-fold, even in
the absence of endoscopy, with significant variability in costs from patient to patient [16].
Among pediatric gastroenterologists, even in the same institution, there was considerable
variation in evaluation and treatment [16,17]. Referral to a gastroenterologist does not
appear to be driven by symptoms but may be driven by pain perception [16]. While costs
are substantially higher in urban settings, this is likely due to the lack of availability of
costly tests and endoscopy in rural facilities, with the costs of evaluation being generated
after referral to an urban care setting. It is also possible that patients in a rural setting
respond better to initial treatment regimens or do not request more expensive tests. It
should be noted that the database does not allow for the estimation of indirect costs of
loss of productivity and, thus, underestimates total costs. In a previous study in The
Netherlands, loss of patient productivity accounted for 22% of overall costs, similar to the
indirect costs in adults [3,15].
Costs could also be affected by the patient’s age and/or race/ethnicity. Our data
would indicate that age does not appear to drive up costs at an encounter level. We found
no differences in encounter costs comparing children and adolescents. We evaluated these
as two separate groups, as a previous study found that most children diagnosed with
recurrent abdominal pain before the age of 12 years did not have persistent symptoms,
while recurrent abdominal pain at the age of 12 years was associated with an increased risk
of an AP-FGID at age 16 years [18]. Certainly, age may affect total patient costs as persistent
symptoms likely create increased encounters. There also appeared to be wide variability in
total direct costs across races, with the highest costs in Hispanic patients and the lowest
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in Native American patients. Both of these groups had a significant number of outliers
making interpretation difficult. Hispanic patients also appeared to be under-represented in
the sample. This could be a classification issue, as the database defines Hispanic as a race
rather than an ethnicity. Again, at a granular cost level, the reasons for these differences
by race are not clear. These could be driven by poorer outcomes, differing sites of care,
or social determinants of health. Previously, our group found a significantly increased
rate of emergency department care for Hispanic and African American patients (in press).
AP-FGIDs are known to be associated with anxiety, depression, stress, and traumatic life
events, all of which are factors which affect treatment response [1,19]. Increased costs could
also be driven by racial disparities in the identification and treatment of mental health
conditions known to affect outcomes, and a poorer response is associated with increased
costs [6,20]. This is an important area for future research.
Costs could also be driven up by co-morbid conditions. A previous study of pediatric
IBS patients demonstrated higher yearly healthcare costs (not limited to costs directly
attributable to IBS) compared to a control group with increased outpatient visits, emergency
department visits, and hospitalizations [8]. These patients also had increased co-morbid
conditions including mental health conditions, substance abuse, migraines, and other
chronic pain conditions which may independently increase costs and impair treatment
response in those patients with IBS [8]. We attempted to limit the effect of co-morbid
conditions by including only patients with a priority 1 AP-FGID diagnosis; however, comorbid conditions likely influenced treatment response. Stress and sleep disturbances
have been shown to negatively impact outcomes [19]. A previous single-site pediatric
study demonstrated a significant increase in costs within partial treatment responders and
non-responders [6].
There also appeared to be cost variability across AP-FGID diagnoses. However,
interpretation of these costs appeared to be affected by the conversion from ICD-9 to ICD10. We analyzed ICD-9 and ICD-10 separately, because the transition to ICD-10 occurred
shortly before the release of Rome IV, which significantly altered the pediatric criteria for
FD and, to a lesser but still substantial degree, for IBS [2]. More importantly, while we
utilized specific diagnostic codes, there was significant variability in how physicians utilize
and interpret Rome criteria, with only moderate rates of agreement even among pediatric
gastroenterologists, making specific AP-FGID diagnoses potentially unreliable [17,21].
While these criteria specifically require symptoms to be present for a minimum of 8 weeks,
there is no way to ensure that symptoms were chronic within the database. Lastly, costs
could also be affected by misdiagnosis, classifying another disease (e.g., inflammatory
bowel disease) as an AP-FGID.
The main weakness is that the database would not capture care delivered at facilities
utilizing a different EHR system. A challenge inherent in this and all pediatric studies
of chronic abdominal pain is the inconsistencies in diagnosing specific AP-FGIDs. The
strength of the current study is that the database allowed for the description of costs
across a large population drawn from multiple sites and across the continuum of care
with wide geographic distribution [22,23]. Utilizing the Health Facts database allowed for
evaluation across centers and across the continuum of care including outpatient, emergency
department, and inpatients settings. Unfortunately, while the database provided total
encounter costs, costs for specific tests or treatments were only available in 3.5% of patients;
consequently, what drove the costs could not be discerned. Importantly, the database
does not allow for reliable assessment of treatment outcomes, which may not only affect
costs but is vital in understanding value. While there is a need to contain costs, higher
short-term costs are not inherently bad if they are associated with better outcomes, which
may decrease the total life-time costs and limit morbidity and disability.
5. Conclusions
There is sufficient variability in costs related to the evaluation and management
of pediatric AP-FGIDs to support multi-site studies to understand the value of specific
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tests and treatments. An existing pediatric model exists in other diseases such as the
ImproveCareNow (ImproveCareNow.org) collaborative study in pediatric inflammatory
bowel disease [24]. Such studies could also move the pediatric community towards the
development of practice guidelines with evaluation and treatment paradigms that improve
outcome while ideally reducing costs. While these conditions are associated with significant
costs, enhancing value should be the primary objective.
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E.F.G.; writing—original draft preparation, M.L., A.S.F., and C.A.F.; writing—review and editing,
M.L., A.S.F., E.F.G., J.V.S., J.M.C., and C.A.F. All authors have read and agreed to the published
version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Data available in Health Facts Database from Cerner Corporation.
Conflicts of Interest: The authors declare no conflict of interest.

References
1.
2.
3.

4.
5.

6.
7.

8.
9.

10.
11.
12.

13.
14.
15.
16.

Korterink, J.; Diederen, K.; Benninga, M.; Tabbers, M. Epidemiology of Pediatric Functional Abdominal Pain Disorders: A
Meta-Analysis. PLoS ONE 2015, 10, e0126982. [CrossRef] [PubMed]
Hyams, J.; Di Lorenzo, C.; Saps, M.; Shulman, R.J.; Staiano, A.; van Tilburg, M. Childhood Functional Gastrointestinal Disorders:
Child/Adolescent. Gastroenterology 2016, 150, 1456–1468.e2. [CrossRef] [PubMed]
Hoekman, D.; Rutten, J.; Vlieger, A.; Benninga, M.A.; Dijkgraaf, M.G.W. Annual Costs of Care for Pediatric Irritable Bowel
Syndrome, Functional Abdominal Pain, and Functional Abdominal Pain Syndrome. J. Pediatr. 2015, 167, 1103–1108.e2. [CrossRef]
[PubMed]
Dhroove, G.; Chogle, A.; Saps, M. A Million-dollar Work-up for Abdominal Pain: Is It Worth It? J. Pediatr. Gastroenterol. Nutr.
2010, 51, 579–583. [CrossRef]
Park, R.; Mikami, S.; LeClair, J.; Bollom, A.; Lembok, C.; Jones, M.; Cheng, V.; Friedlander, E.; Nurko, S. Inpatient burden of
childhood functional GI disorders in the USA: An analysis of national trends in the USA from 1997 to 2009. Neurogastroenterol.
Motil. 2015, 27, 684–692. [CrossRef]
Mani, J.; Madani, S.; Thomas, R. Economic impact and prognostic factors of functional dyspepsia in children. J. Pediatr.
Gastroenterol. Nutr. 2020, 70, e65–e70. [CrossRef]
Tack, J.; Stanghellini, V.; Mearin, F.; Yiannakou, Y.; Layer, P.; Coffin, B.; Simren, M.; Mackinnon, J.; Wiseman, G.; Marciniak,
A.; et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC
Gastroenterol. 2019, 19, 69. [CrossRef]
Beinvogl, B.; Palmer, N.; Kohane, I.; Nurko, S. Healthcare spending and utilization for pediatric irritable bowel syndrome in a
commercially insured population. Neurogastroenterol. Motil. 2021, 33, e14147. [CrossRef]
Jakovljevic, M.; Fernandes, P.O.; Teixeira, J.P.; Rancic, N.; Timofeyev, Y.; Reshetnikov, V. Underlying differences in health spending
within the World Health Organisation Europe Region- Comparing EU15, EU Post-2004, CIS, EU Candidate and CARINFONET
countries. Int. J. Environ. Res. Public Health 2019, 16, 3043. [CrossRef]
Jakovljevic, M.; Timofeyev, Y.; Ekkert, N.V.; Fedorova, J.V.; Skvirskaya, G.; Bolevich, S.; Reshetnikov, V.A. The impact of health
expenditures on public health in BRICS nations. J. Sport Health Sci. 2019, 8, 516–519. [CrossRef]
Global Burden of Disease Child and Adolescent Health Collaboration. Child and adolescent health from 1990 to 2015: Findings
from the global burden of diseases, injuries, and risk factors 2015 study. JAMA Pediatr. 2017, 171, 573–592. [CrossRef] [PubMed]
Global Burden of Disease Health Financing Collaborator Network. Evolution and patterns of global health financing 1995–2014:
Development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet
2017, 389, 1981–2004. [CrossRef]
Inadomi, J.M.; Fennerty, M.B.; Bjorkman, D. Systematic review: The economic impact of irritable bowel syndrome. Aliment.
Pharm. 2003, 18, 671–682. [CrossRef] [PubMed]
Canavan, C.; West, J.; Card, T. Review article: The economic impact of the irritable bowel syndrome. Aliment. Pharm. 2014, 40,
1023–1034. [CrossRef] [PubMed]
Zhang, F.; Xiang, W.; Li, C.Y.; Li, S.C. Economic burden of irritable bowel syndrome in China. World J. Gastroenterol. 2016, 22,
10450–10460. [CrossRef]
Lane, M.M.; Weidler, E.M.; Czyzewski, D.I.; Shulman, R.J. Pain symptoms and stooling patterns do not drive diagnostic costs for
children with functional abdominal pain and irritable bowel syndrome in primary or tertiary care. Pediatrics 2009, 123, 758–764.
[CrossRef]

Children 2021, 8, 985

17.
18.

19.
20.
21.
22.
23.
24.

9 of 9

Schurman, J.V.; Hunter, H.L.; Friesen, C.A. Conceptualization and treatment of chronic abdominal pain in pediatric gastroenterology practice. J. Pediatr. Gastroenterol. Nutr. 2010, 50, 32–37. [CrossRef]
Sjölund, J.; Uusijärvi, A.; Tornkvist, N.T.; Kull, I.; Bergström, A.; Alm, J.; Törnblom, H.; Olén, O.; Simrén, M. Prevalence and
progression of recurrent abdominal pain, from early childhood to adolescence. Clin. Gastroenterol. Hepatol. 2021, 19, 930–938.
[CrossRef]
Deacy, A.D.; Friesen, C.A.; Staggs, V.S.; Schurman, J.V. Evaluation of clinical outcomes in an interdisciplinary abdominal clinic: A
retrospective, exploratory review. World J. Gastroenterol. 2019, 25, 3079–3090. [CrossRef]
Alegria, M.; Vallas, M.; Pumariega, A. Racial and ethnic disparities in pediatric mental health. Child Adolesc. Psychiatr. Clin. N Am.
2010, 19, 759–774. [CrossRef]
Chogle, A.; Dhroove, G.; Sztainberg, M.; Di Lorenzo, C.; Saps, M. How reliable are the Rome III criteria for the assessment of
functional gastrointestinal disorders in children? Am. J. Gastroenterol. 2010, 105, 2697–2701. [CrossRef] [PubMed]
Glynn, E.F.; Hoffman, M.A. Heterogeneity introduced by HER system implementation in a de-identified data resource from 100
non-affiliated organizations. JAMIA Open 2019, 2, 554–561. [CrossRef] [PubMed]
DeShazo, J.P.; Hoffman, M.A. A comparison of a multistate inpatient EHR database to the HCUP Nationwide Inpatient Sample.
BMC Health Serv. Res. 2015, 15, 384. [CrossRef] [PubMed]
Seid, M.; Hartley, D.M.; Dellal, G.; Myers, S.; Margolis, P.A. Organizing collaboration: An actor-oriented architecture in
ImproveCareNow. Learn. Health Syst. 2020, 4, e10205. [CrossRef]

